PLoS ONE (Jan 2014)

Impact of an altered PROX1 expression on clinicopathology, prognosis and progression in renal cell carcinoma.

  • Tao Lv,
  • Yanfeng Liu,
  • Jianping Zhang,
  • Le Xu,
  • Yu Zhu,
  • Hankun Yin,
  • Huimin An,
  • Zongming Lin,
  • Youhua Xie,
  • Lian Chen

DOI
https://doi.org/10.1371/journal.pone.0095996
Journal volume & issue
Vol. 9, no. 5
p. e95996

Abstract

Read online

The transcription factor PROX1 (prospero homeobox 1) has a critical role in the development of various organs, and has been implicated in both oncogenic and tumor-suppressive functions in human cancers. However, the role of PROX1 in the development of renal cell carcinomas (RCCs) has not yet been studied. Here, we reported that PROX1 expression was decreased in human RCC tissues compared with adjacent normal tissues. In RCC tissues, however, poorly differentiated RCC expressed higher PROX1 levels compared with well-differentiated RCC. In addition, the PROX1 immunostaining levels were positively correlated with tumor nuclear grade and lymph node metastasis. Further, high PROX1 expression indicated poor survival for patients. These findings imply that in the different developmental stages of RCC, PROX1 may exert distinct functions according to the specific microenvironment of tumor. Moreover, in vitro experiments revealed that PROX1 overexpression enhanced the proliferation and migration of RCC cells; conversely, PROX1 depletion by siRNA attenuated the proliferation and migration of RCC cells. Collectively, these observations suggest that PROX1 plays an important role in RCC development and progression, and PROX1 may be a novel target for prevention and treatment of RCC.